Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Poseida Therapeutics on Thursday signed a strategic global collaboration with Roche to develop and commercialize allogeneic CAR-T cell therapies, in a deal…
Roche has agreed to pay Poseida Therapeutics up to $6 billion in upfront, equity, and milestone payments for global rights to develop and commercialize the…
Poseida 8-K (Jan 2025): completion of merger with Blue Giant Acquisition Corp., Roche subsidiary; shares converted to right to receive $9.00 plus CVR; Poseida…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
In August 2022, Poseida Therapeutics and Roche entered a strategic global collaboration on allogeneic (off-the-shelf) CAR-T therapies for hematologic malignancies including multiple myeloma and B-cell lymphomas. Roche paid $110M upfront (plus a ~$50M equity investment) and committed up to ~$6B in development, regulatory and commercial milestones, with tiered royalties. Lead programs were P-BCMA-ALLO1 (allogeneic BCMA CAR-T) and P-CD19CD20-ALLO1. The partnership matured and expanded through 2024, with Poseida receiving additional milestone payments. On November 26, 2024 Roche moved to acquire Poseida outright for $9.00/share (~$1.0B) plus a non-tradeable CVR of up to $4.00/share (total up to ~$1.5B); the acquisition closed January 8, 2025 via Blue Giant Acquisition Corp., delisting Poseida from Nasdaq and folding the collaboration and its allogeneic CAR-T platform fully into Roche.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Roche Holding AG / Poseida Therapeutics (this deal) | 2022 | $6.1B | — |
| Roche Holding AG / Chugai Pharmaceutical Co. Ltd. | 2002 | $1.4B | 100 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| Roche Holding AG / Corange Ltd. (Boehringer Mannheim Group) | 1997 | $11.0B | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2007 | $3.4B | 88 |
| Roche Holding AG / Foundation Medicine, Inc. | 2015 | $1.1B | 87 |
| Roche Holding AG / Foundation Medicine, Inc. | 2018 | $5.3B | 85 |
← Browse all deals · How we score deals
More: 2022 deals · Roche Holding AG deals · Hematology deals